^
    Back
    Association details:
    Biomarker:MET positive + EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor) +
    Tabrecta (capmatinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JCO Precis Oncol
    Title:

    Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer

    Published date:
    01/14/2021
    Excerpt:
    A standard 3 + 3 dose-escalation trial of capmatinib in combination with erlotinib in patients with MET-positive NSCLC was used….Cohort A included 12 patients with EGFR-mutant tumors resistant to TKIs....The overall response rate (ORR) and DCR in dose-expansion cohort A was 50% and 50%, respectively. In cohort B, the ORR and disease control rate were 75% and 75%.
    DOI:
    10.1200/PO.20.00279